Early Identification of Markers in Alzheimer's Families / ALFA

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

419 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-10-25

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The ALFA study is a long term, prospective, observational study of AD patients' adult children aimed at studying and characterizing key physio-pathological features of the preclinical phase of AD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants

NCT02685969

Alzheimer's Disease

RECRUITING

Characterization of Cerebral Tau Aggregates With 18F-RO6958948 PET in the ALFA Population

NCT04482660

Healthy Mild Cognitive Impairment

ENROLLING_BY_INVITATION NA

Neuroimaging Markers of Alzheimer Disease: a Longitudinal Population Study

NCT01582919

Dementia Alzheimer Disease

COMPLETED NA

Biomarkers of Cognitive Impairment in Blood Cells

NCT05582941

Mild Cognitive Impairment Due to Alzheimer's Disease Dementia Due to Alzheimer's Disease (Disorder)

COMPLETED

Multi-modal Neuroimaging in Alzheimer's Disease

NCT01638949

Alzheimer's Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The natural history of AD includes an asymptomatic or preclinical phase characterized by pathological cerebral alterations without any evident symptoms of the disease. The beginning of the preclinical phase can be detected using a series of biological and neuroimaging markers that indicate the presence of Aβ deposition in the brain. A variety of factors such as inflammation, genetic load (e.g., APOE4), diet, cardiovascular risk, sleep disorders and cognitive reserve, produced by endogenous or exogenous factors, vary among individuals and may determine the beginning and evolution of the preclinical phase of the disease. It is possible to identify subclinical, biological, cognitive and neuroimaging changes, in the AD preclinical phase. The longitudinal study of intra-individual changes will be more sensitive than cross-sectional inter-individual studies to detect the cognitive evolution during the AD preclinical phase. Similarly, it would be possible to identify factors in subjects at the preclinical phase that will influence their evolution to the clinical stage of the disease.

The study will start with a screening of 3.000 recruited volunteers (NCT01835717) complying as much as possible with study selection criteria and perfectly aware of the study needs.

The selected 400 participants fulfilling the inclusion criteria will undergo detailed phenotyping consisting in: clinical history, AD family history, full cognitive evaluation, cognitive reserve determination, CSF sample collection, blood and urine sample collection, neuroimaging (MRI), quality of life and habits of life questionnaires (physical activity, diet, sleeping habits, social activity, toxics habits, pollution exposure).

The longitudinal study will consist in a every 3-year follow-up visit in which the participant will undergo a review of the clinical history data, a full cognitive evaluation, neuroimaging (MRI), samples collection (blood, urine, CSF) and update of the life habits changes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adult children of AD patient

Cognitively healthy adult children of AD patient: First-degree descendant of an AD patient (following diagnosis as define in protocol) from 45 to 64 years old.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult children of AD patient: First-degree descendant of an AD patient (following diagnosis as define in protocol).
* Age: 45 to 64 years old.
* Long-term commitment to the study: baseline and follow-up visits. Potential participants have to agree to undergo to all the procedures described in the protocol.

Exclusion Criteria

* Cognitive impairment: to be included the participant must show no signs of objective cognitive impairment.
* Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol.
* Illiteracy or functional illiteracy.
* Any contraindication to any test or procedure at the time of study inclusion.
* Family history of monogenic AD.
* Not willing to undergo one or more of the tests and procedures described in the protocol at baseline.

Minimum Eligible Age

45 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes